Just started -- but it's been brewing for a while, as both @ledaberio.bsky.social and I have been much inspired by recent very cool work by many others, especially @thebusyowl.bsky.social, Elizabeth Schechter, and Daniela Dover

This article raises concerns about the lack of consideration of potential harms of this technology for clinical trial participants, and current and future users.

There is increased enthusiasm about the use of Artificial Intelligence (AI) technologies in psychotherapy. Notably, AI psychotherapy chatbots are increasing in popularity, especially since the US Food and Drug Administration (FDA) gave one of these apps breakthrough device designation.

Open Peer Commentary (OPC) proposals of roughly one paragraph are due Monday, November 10th. Please submit your proposal via the AJOB Editorial site: mc.manuscriptcentral.com/uajb

Thank you! and indeed; it is astounding how there is no oversight or regulation.

There is not a lot of transparency about the design of these apps, that is part of the challenge in assessing their potential efficacy. We talk about this a little bit in this paper: www.tandfonline.com/doi/full/10....

I am heading to Greece now to meet up with my sisters and mom and have some off work time on the Aegean coast before I start the next bout of book touring.

The highlight of the week was @madva.bsky.social’s lecture on Bias in Medicine. Students, colleagues and I benefited tremendously from Alex’s rigorous, empirically grounded, and hope building expertise. The vibes were high! Thanks Alex!!!

ditto!